Synonym
Piribedil Dihydrochloride; Piribedil 2HCl;
IUPAC/Chemical Name
2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Dihydrochloride
InChi Key
LTXWEVPOJXPWAD-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H18N4O2.2ClH/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14;;/h1-5,10H,6-9,11-12H2;2*1H
SMILES Code
[H]Cl.[H]Cl.C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
371.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Pilipovich AA, Golubev VL. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(6):83-90. doi: 10.17116/jnevro20171176183-90. Review. Russian. PubMed PMID: 28745677.
2: Zakharov VV, Gromova DO. [Current approaches to management of patients with mild cognitive impairment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3):107-112. doi: 10.17116/jnevro201711731107-112. Review. Russian. PubMed PMID: 28399106.
3: Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5. Review. PubMed PMID: 27344665.
4: Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. Mov Disord. 2015 Sep 15;30(11):1490-504. doi: 10.1002/mds.26415. Review. PubMed PMID: 26371623.
5: Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Review. Erratum in: Br J Psychiatry. 2014 Jan;204(1):81. PubMed PMID: 24085737; PubMed Central PMCID: PMC3943830.
6: Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829. Review. PubMed PMID: 22021173.
7: Gouraud A, Millaret A, Descotes J, Vial T; French Association of Regional Pharmacovigilance Centres. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol. 2011 May-Jun;34(3):104-7. doi: 10.1097/WNF.0b013e31821f0d8b. Review. PubMed PMID: 21586915.
8: Millan MJ. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther. 2010 Nov;128(2):229-73. doi: 10.1016/j.pharmthera.2010.06.002. Epub 2010 Jun 26. Review. PubMed PMID: 20600305.
9: Mil'chakova AE, Popov GR, Bykov AV, Gekht AB. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):49-55. Review. Russian. PubMed PMID: 18567194.
10: Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs. 2008;22(7):563-86. Review. PubMed PMID: 18547126.
11: Vale S. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? Exp Biol Med (Maywood). 2008 Aug;233(8):941-51. doi: 10.3181/0707-MR-193. Epub 2008 Jun 5. Review. PubMed PMID: 18535172.
12: Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther. 2006 Jan;28(1):1-12. Review. PubMed PMID: 16490575.
13: Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Clin Pharmacokinet. 2006;45(2):109-36. Review. PubMed PMID: 16485914.
14: Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May;20(5):523-39. Review. PubMed PMID: 15818599.
15: Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. Review. PubMed PMID: 15298067.
16: Gekht AB. [Treatment of Parkinson's disease: use of piribedil]. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(1):54-6. Review. Russian. PubMed PMID: 14870695.
17: Boĭko AN, Batysheva TT, Chikina ES, Artemova IIu, Vdovichenko TV, Ismailov AM, Obydenova NA, Osipenko LN, Rotor LD, Vinevitskiĭ IaIa, Nesterova VA. [Dopamine receptor agonists in treatment of outpatient patients with Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2003;103(9):54-8. Review. Russian. PubMed PMID: 14571675.
18: Gekht AB. [Use of dopamine analogs in Parkinson's disease treatment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(12):53-5. Review. Russian. PubMed PMID: 12520782.
19: Gekht AB. [Use of dopamine agonists in the treatment of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):54-8. Review. Russian. PubMed PMID: 12378886.
20: DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease. Mov Disord. 2002;17 Suppl 4:S90-2. Review. PubMed PMID: 12211147.
